Related Experiment Video

Updated: May 5, 2026

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation
07:53

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

33.2K

Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review

Ya-Qi Xiao1, Jiao Long1, Shuang-Shuang Zhang1

  • 1School of Chemical Engineering and Pharmacy, Pharmaceutical Research Institute, Wuhan Institute of Technology, Wuhan 430205, China.

Bioorganic Chemistry
|April 18, 2024
PubMed

Insights

Researchers reviewed non-peptidic inhibitors targeting the main protease (Mpro) of SARS-CoV-2. These compounds show promise for developing effective COVID-19 antiviral drugs and broad-spectrum coronavirus treatments.

Area of Science:

  • * Virology and Drug Discovery
  • * Medicinal Chemistry

Background:

  • * The COVID-19 pandemic necessitates the development of effective antiviral therapies.
  • * Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) main protease (Mpro) is a critical enzyme for viral replication and a prime target for drug development.
  • * Non-peptidic inhibitors offer advantages in antiviral activity and metabolic stability compared to other drug classes.

Purpose of the Study:

  • * To provide a comprehensive overview of research on non-peptidic SARS-CoV-2 Mpro inhibitors developed since 2020.
  • * To analyze the molecular structures, structure-activity relationships (SARs), biological activities, and binding mechanisms of these inhibitors.
  • * To offer insights for the advancement of anti-SARS-CoV-2 agents and broad-spectrum coronavirus Mpro inhibitors.

Main Methods:

  • * Literature review of scientific publications and research data.
  • * Analysis of molecular structures and structure-activity relationships (SARs) of identified inhibitors.
  • * Evaluation of biological activity data and binding modes with SARS-CoV-2 Mpro.

Main Results:

  • * Significant progress has been made in identifying and characterizing non-peptidic inhibitors of SARS-CoV-2 Mpro.
  • * Detailed SAR studies have elucidated key structural features contributing to inhibitor efficacy.
  • * Understanding of inhibitor binding modes provides a basis for rational drug design.

Conclusions:

  • * Non-peptidic Mpro inhibitors represent a promising therapeutic strategy against SARS-CoV-2.
  • * Continued research into these compounds can lead to the development of novel antiviral drugs.
  • * Findings support the potential for broad-spectrum coronavirus Mpro inhibitor development.
Keywords:
Broad spectrumCOVID-19Covalent inhibitorsDrug designMain proteaseNon-covalent inhibitorsNon-peptidic inhibitorsSARS-CoV-2

More Related Videos

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods10:40

Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods

Published on: December 21, 2019

26.0K
Engineering Antiviral Agents via Surface Plasmon Resonance13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.3K

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
72.4K
Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
21.1K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
106
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58